CampETEC is under clinical development by Immuron and currently in Phase II for Campylobacter Infections. According to GlobalData, Phase II drugs for Campylobacter Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CampETEC LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CampETEC overview

Antibody is under development for the prevention of infectious diarrhea caused by campylobacteriosis and enterotoxigenic Escherichia coli (ETEC). It is administered through oral route. The therapeutic candidate is being developed based on polyclonal antibody platform.

Immuron overview

Immuron is a biopharmaceutical company that commercializes and develops a novel class of specifically targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. The company’s product pipeline includes IMM 124E and IMM 529. Its pipeline candidates treat diarrhea, clostridioides difficle infection, campylobacteriosis, enterotoxigenic escherichia coli (ETEC) infections and shigellosis (bacillary dysentery). It markets its products under the brand names Travelan and Protectyn. Immuron develops an oral immunotherapy platform that improves the immunological balance by orally administering safe compounds. The company works in partnership with the National Institute of Health, Monash University, WRAIR, Treidlia BioVet, Synalit, The University of Melbourne and CSIRO. Immuron is headquartered in Carlton, Victoria, Australia.

For a complete picture of CampETEC’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.